MedTrace Logo

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

NCT00987727 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2011-09-21

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.

Conditions

  • Dry Eye Syndromes
  • Keratoconjunctivitis Sicca

Interventions

DRUG

carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)

One drop in each eye three to six times daily, as needed

DRUG

sodium hyaluronate 0.18% (VISMED® Multi)

One drop in each eye three to six times daily, as needed

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-07-31
Completion
2010-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987727 on ClinicalTrials.gov